| Huang ST |
------>authors3_c=??? ------>paper_class1=1 ------>Impact_Factor=2.662 ------>paper_class3=2 ------>paper_class2=1 ------>vol=16 ------>confirm_bywho=cmshih ------>insert_bywho=cmlin ------>Jurnal_Rank=31.7 ------>authors4_c= ------>comm_author= ------>patent_EDate=None ------>authors5_c= ------>publish_day=15 ------>paper_class2Letter=None ------>page2=26 ------>medlineContent= ------>unit=E0103 ------>insert_date=20081018 ------>iam=3 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN=0968-0896 ------>authors_c=??? ------>score=500 ------>journal_name=Bioorg Med Chem. ------>paper_name=Development and biological evaluation of C(60) fulleropyrrolidine-thalidomide dyad as a new anti-inflammation agent. ------>confirm_date=20081018 ------>tch_id=081006 ------>pmid=18723357 ------>page1=8619 ------>fullAbstract=Research studies in the field of C(60) fullerene derivatives have significantly increased due to the broad range of biological activities that were found for these compounds. We designed and prepared a new C(60) fullerene hybrid bearing thalidomide as a potential double-action anti-inflammatory agent, capable of simultaneous inhibition of LPS-induced NO and TNF-alpha production. The C(60) fulleropyrrolidine-thalidomide dyad, CLT, was an effective agent to suppress the release of NO and TNF-alpha by the LPS-stimulated macrophages RAW 264.7. Ten micromolars of CLT effectively inhibited LPS-induced NO and TNF-alpha production by 47.3+/-4.2% and 70.2+/-4% with respected to the control, respectively. Furthermore, preliminary biochemical investigation revealed that CLT was a potent agent to suppress both LPS-induced intracellular ROS production and iNOS expression, and CLT also inhibited the phosphorylation of ERK which is an important protein kinase involved in the activation of TNF-alpha synthesis in LPS-activated macrophages. We believed that the studies herein would hold promise for future development of a new generation of potent anti-inflammatory agents. ------>tmu_sno=None ------>sno=18922 ------>authors2=Ho CS ------>authors3=Lin CM ------>authors4=Fang HW ------>authors5=Peng YX ------>authors6= ------>authors6_c= ------>authors=Huang ST ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=??? ------>publish_area=0 ------>updateTitle=Development and biological evaluation of C(60) fulleropyrrolidine-thalidomide dyad as a new anti-inflammation agent. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no=18 ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2008 ------>submit_flag=None ------>publish_month=9 |